Drug intelligence / Profile preview

repibresib

Development stage: Unknown
Lead developer: Vyne Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

Repibresib (VYN201) is a topical, small molecule pan-bromodomain and extra-terminal domain (BET) inhibitor being developed by VYNE Therapeutics for the treatment of nonsegmental vitiligo. It targets BRD2, BRD3, BRD4, and BRDT proteins, which are epigenetic regulators of gene transcription involved in inflammatory pathways. Designed as a 'soft drug,' repibresib is intended for local action with minimal systemic exposure to reduce potential side effects. The compound was originally licensed from Tay Therapeutics and is currently in Phase 2b clinical development.

Targets

BRD2 (Bromodomain-containing protein 2)BRDT (Bromodomain testis-specific protein)BRD4 (Bromodomain-containing protein 4)BRD3 (Bromodomain-containing protein 3)

Beyond the preview

Go deeper on repibresib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on repibresib.

Explore the full profile